Abstract:In recent years, multidrug-resistant pathogenic microorganisms (MDROs) have emerged as a severe threat to human health, exhibiting robust resistance to traditional antibiotics. This has created a formidable challenge in modern medicine as we grapple with limited options to combat these resilient bacteria. Despite extensive efforts by scientists to develop new antibiotics targeting these pathogens, the quest for novel antibacterial molecules has become increasingly arduous. Fortunately, nature offers a potential solution in the form of cationic antimicrobial peptides (AMPs) and their synthetic counterparts. AMPs, naturally occurring peptides, have displayed promising efficacy in fighting bacterial infections by disrupting bacterial cell membranes, hindering their survival and reproduction. These peptides, along with their synthetic mimics, present an exciting alternative in combating antibiotic resistance. They hold the potential to emerge as a formidable tool against MDROs, offering hope for improved strategies to protect communities. Extensive research has explored the diversity, history, and structure-properties relationship of AMPs, investigating their amphiphilic nature for membrane disruption and mechanisms of action. However, despite their therapeutic promise, AMPs face several documented limitations. Among these challenges, poor pharmacokinetic properties stand out, impeding the attainment of therapeutic levels in the body. Additionally, some AMPs exhibit toxicity and susceptibility to protease cleavage, leading to a short half-life and reduced efficacy in animal models. These limitations pose obstacles in developing effective treatments based on AMPs. Furthermore, the high manufacturing costs associated with AMPs could significantly hinder their widespread use. In this review, we aim to present experimental and theoretical insights into different AMPs, focusing specifically on antibacterial peptides (ABPs). Our goal is to offer a concise overview of peptide-based drug candidates, drawing from a wide array of literature and peer-reviewed studies. We also explore recent advancements in AMP development and discuss the challenges researchers face in moving these molecules towards clinical trials. Our main objective is to offer a comprehensive overview of current AMP and ABP research to guide the development of more precise and effective therapies for bacterial infections.

Engineering ribosomally synthesized and posttranslationally modified peptides as new antibiotics

Recent Advances in Discovery, Bioengineering, and Bioactivity-Evaluation of Ribosomally Synthesized and Post-translationally Modified Peptides

A Scalable Platform to Discover Antimicrobials of Ribosomal Origin

Mining and Biosynthesis of Bioactive Lanthipeptides from Microorganisms.

Discovery and Engineering of Ribosomally Synthesized and Post-Translationally Modified Peptide (ripp) Natural Products

Nonribosomal Antibacterial Peptides That Target Multidrug-Resistant Bacteria.

Advancements in the Application of Ribosomally Synthesized and Post-Translationally Modified Peptides (RiPPs)

Prospects of In vivo Incorporation of Non-canonical Amino Acids for the Chemical Diversification of Antimicrobial Peptides

Opportunities and challenges of RiPP-based therapeutics

Genome mining for ribosomally synthesized and post-translationally modified peptides (RiPPs) in anaerobic bacteria

Advancements in peptide-based antimicrobials: A possible option for emerging drug-resistant infections

Challenges and advances in genome mining of ribosomally synthesized and post-translationally modified peptides (RiPPs)

Antimicrobial Peptides: A Promising Therapeutic Strategy in Tackling Antimicrobial Resistance

Microbial-derived peptides with anti-mycobacterial potential

Antimicrobial Peptides: Recent Insights on Biotechnological Interventions and Future Perspectives

Synthetic molecular evolution of antimicrobial peptides

[Progress on the design and optimization of antimicrobial peptides]

Rule-based omics mining reveals antimicrobial macrocyclic peptides against drug-resistant clinical isolates

Novel types of RiPP-modifying enzymes

New developments in RiPP discovery, enzymology and engineering

Using chemical synthesis to optimise antimicrobial peptides in the fight against antimicrobial resistance